Clinical Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Immunocompromised Transplant Patients

An Observational, Multi-center, Prospective and Retrospective Clinical Study to Evaluate the Performance of the NeuMoDx™ EBV Quant Assay 2.0 on the NeuMoDx™ Molecular Systems in Immunocompromised Transplant Patients

The NeuMoDx EBV Quant Assay 2.0 study is a multi-center, observational clinical investigation designed to evaluate the performance of the NeuMoDx EBV Quant Assay 2.0 in quantifying Epstein-Barr virus (EBV) DNA levels in plasma samples from immunocompromised transplant patients. The study compares the NeuMoDx EBV assay's performance against an FDA-cleared comparator assay under routine clinical use conditions, utilizing both the NeuMoDx™ 96 and NeuMoDx™ 288 Molecular Systems. The aim is to demonstrate the quantitative concordance and clinical utility of the assay in monitoring EBV DNA levels as part of patient management.

Study Overview

• Status: Completed
• Conditions: EBV Viremia
• Intervention / Treatment: Diagnostic test: NeuMoDx EBV Quant 2.0 Assay

Detailed Description

This study is an observational, multi-center, open-labeled, prospective, and retrospective clinical evaluation aimed at assessing the performance of the NeuMoDx EBV Quant Assay 2.0 on the NeuMoDx™ 96 and NeuMoDx™ 288 Molecular Systems. Plasma samples are collected from immunocompromised patients undergoing solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT) who are at risk of EBV infection or reactivation. The study includes both fresh and frozen plasma specimens obtained as part of routine clinical care.

The primary objective is to demonstrate the quantitative concordance of the NeuMoDx EBV assay when compared to the cobas® EBV assay (Roche Diagnostics Corporation) using a predefined set of performance criteria. The study also assesses the equivalence of performance between the two NeuMoDx systems (NeuMoDx™ 96 and NeuMoDx™ 288) in quantifying EBV DNA levels across a range of clinical specimens. Secondary objectives include evaluating the assay's performance across different viral load concentrations and subgroups.

• Study Type: Observational
• Enrollment (Actual): 1070

Contacts and Locations

Study Locations

• United Kingdom
  • Manchester, United Kingdom, M130BH
    • QIAGEN Gaithersburg, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Standard of care for transplant patients undergoing immuno suppression

Description

Inclusion Criteria:

• Immunocompromised transplant patients (Solid Organ Transplant (SOT) or Hematopoietic Stem Cell Transplant (HSCT)).
• Fresh and frozen plasma specimens derived from whole blood collected with EDTA as an anticoagulant.
• Residual fresh or frozen EDTA plasma specimens obtained from routine testing, including specimens collected from the same subject at different timepoints.
• Sufficient sample volume 1.6- 2.0 ml for testing with 2 assays plus discordant testing.
• EDTA plasma samples have been stored under the following conditions:
• 2-8° C up to 7 days and/or -20° C +/- 2° C or colder for up to 6 months following the separation of plasma from whole blood. Or fresh EDTA plasma samples that have not been stored loaded onto the NeuMoDx™ system immediately after they have been separated from whole blood.
• Frozen samples have not gone through more than two freeze/thaw cycles.

Exclusion Criteria:

• Specimens not collected according to the manufacturer's instructions or study protocol.
• Lack of clear subject identification or label on a residual plasma sample
• Unable to obtain required medical chart information.
• Obvious physical damage to the residual sample.
• Specimens that have remained onboard the NeuMoDx System for longer than 8 hours prior to processing.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Demonstration that the NeuMoDx™ EBV Quant Assay 2.0 achieves its intended performance during normal conditions of use by the intended user in the intended environment	The concordance of the NeuMoDx™ EBV Quant Assay 2.0 to a comparator's test shall meet these performance metrics with EBV-positive samples within the linear range of the NeuMoDx™ EBV Quant Assay 2.0: Slope (m): 0.9 ≤ m ≤1.1; R2 ≥ 0.90, or p-value ≥ 0.05 Due to the variance in EBV qPCR assays, the Intercept (b) of the linearity fit will be characterized with an anticipated range of -1.0 to +1.0 Log10(IU/mL). Percent agreement above the threshold (>LoD/LLoQ) of the reference method shall be > 95%, with the lower confidence interval to be > 80%. Percent agreement below the threshold (<LoD/LLoQ) of the reference method shall be > 95%, with the lower confidence interval to be > 90%."	the primary outcome was assessed a single time after collecting and testing specimens over a 19 month duration

Collaborators and Investigators

• Sponsor: QIAGEN Gaithersburg, Inc
• Investigators: Study Director: Sarah Johnson, QIAGEN Gaithersburg, Inc

Study record dates

Study Major Dates

• Study Start (Actual): August 31, 2022
• Primary Completion (Actual): December 31, 2023
• Study Completion (Actual): March 15, 2024

Study Registration Dates

• First Submitted: October 31, 2024
• First Submitted That Met QC Criteria: November 7, 2024
• First Posted (Estimated): November 8, 2024

Study Record Updates

• Last Update Posted (Estimated): November 8, 2024
• Last Update Submitted That Met QC Criteria: November 7, 2024
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Infections; Virus Diseases; Sepsis; Systemic Inflammatory Response Syndrome; Inflammation; Viremia
• Other Study ID Numbers: SMF-21-2132-1-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No